A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...